Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

module 2b > VTE formulary > Flashcards

VTE formulary Flashcards

1
Q

Unfractionated heparin bran

A

UFH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Exonaparin brand

A

Lovenox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Dalteparin brand

A

Fragmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Tinzaparin brand

A

Innohep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fondaparinux brand

A

Arixtra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Rivaroxaban brand

A

Xarelto

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Edoxaban brand

A

Savaysa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Apixaban brand

A

Eliquis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bivalirudin brand

A

Angiomax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dabigatran brand

A

Pradaxa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

tPA, Alteplase brand

A

Activase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Reteplase brand

A

Retevase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tenecteplase brand

A

Tnkase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Urokinase brand

A

Abbokinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Warfarin bran

A

Coumadin, Jantoven

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

UFH dose

A 
IV or SQ (not IM)
Old standard: 
5000 u IV bolus + 1000-1200units/hour
Subcutaneous:
Prophylaxis—5000 u SQ q8-12h (12 if less than 50mL/min CrCl)
Treatment—17500 u SQ q12h
Weight based (recommended):
(80 u)/(kg actual body weight) IV bolus + 18 u/kg/hr inf.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

UFH SE

A 
Major bleeding
Osteoporosis (if long term)
Hypersensitivity
HIT
HAT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

UFH monitoring

A

aPTT (therapeutic range 1.5-2.5 times normal)
•Baseline
•6 hours after dose or dose change (x24h)
•`Daily after 1st day

Platelet QOD until day 14

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

lovenox dosing

A 
Prophylaxis:
30mg SQ q12h
40mg SQ daily
Treatment: (actual body weight)
1mg/kg SQ q12h
1.5mg/kg SQ daily
If CrCl less than 30mL/min:
Prophylaxis—30mg SQ daily
Treatment—1mg/kg SQ daily
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

dalteparin dosing

A

Prophylaxis:
2500-5000 IU SQ daily
Treatment:
200 IU/kg SQ daily (MAX 18000 IU)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

tinzaparin dosing

A

Treatment:

175 anti-Xa IU/kg SQ daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

enoxaparin, dalteparin and tinzaparin SE

A

Black box warning:
Do NOT use with neural anesthesia/spinal puncture.

Bleeding
Thrombocytopenia (less than UFH)
Delayed HS skin reactions

23
Q

enoxaparin, dalteparin and tinzaparin monitoring

A

If CrCl less than 30mL/min (severe kidney failure), children, obesity, long courses, pregnancy, monitor anti-Xa level 4-6h post.

  • -BID goal 0.6-1u/mL peak
  • -QD goal 0.1-0.3u/mL trough (or 1-2u/mL peak)

Goal 0.5-1.5 in dalteparin less than 30mL/min CrCl.

24
Q

fondaparinux dosing

A 
Prophylaxis:
2.5mg SQ daily (not for less than 50kg or CrCl less than 30mL/min)
Treatment:
less than 50kg: 5mg SQ daily
50-100kg: 7.5mg SQ daily
over 100kg: 10mg SQ daily
25
Q

fondaparinux SE

A

bleeding

26
Q

fondaparinux monitoring

A

Can monitor anti-Xa levels, but no routine monitoring

27
Q

rivaroxaban dosing

A

DVT prophylaxis: (6-10h post surgery)
10mg PO daily for 35 days in THA, 12 dahs TKA
DVT/PE treatment:
15mg PO BID x3 weeks, then 20mg daily with food
NV Atrial fibrillation:
20mg PO daily (15mg if CrCl 15-50mL/min)
Secondary prevention:
20mg PO daily for 6-12 mos, after initial 6-12 mo tx

28
Q

rivaroxaban SE

A

Bleeding

Black box spinal/epidural hematoma and premature D/C increases risk thrombotic event

29
Q

edoxaban dosing

A

DVT/PE treatment (after 5-10 days parenteral therapy):
60mg PO daily if CrCl >50 mL/min
30mg PO daily if CrCl 15-50 mL/min, body weight ≤60kg, or Pgp inhibitors
NV atrial fibrillation:
60mg PO daily if CrCl 50-95 mL/min
30mg PO daily if CrCl 15-50 mL/min

30
Q

edoxaban SE

A

Bleeding
Black box spinal/epidural hematomas, premature discontinuation increases risk thrombotic event
Less efficacy in NVAF patient CrCl >95 mL/min

31
Q

apixaban dosing

A

DVT prophylaxis:
2.5mg PO BID
DVT/PE treatment:
10mg PO BID x7 days, then 5mg BID x6 mos (2.5 after)
NV atrial fibrillation:
5mg PO BID
2.5mg PO BID if 2 of:
age at or above 80 years, weight 60kg or less, SCr 1.5mg/dL or higher
OR dialysis + age over 80 years OR weight under 60kg

32
Q

apixaban SE

A

Bleeding

Black box spinal/epidural hematomas, premature discontinuation increases risk thrombotic event

33
Q

lepirdin dosing

A

HIT:

0.15 mg/kg/h (± 0.4 mg/kg bolus)

34
Q

lepirudin SE

A

bleeding

35
Q

lepirdun monitoring

A

Goal aPTT 1.5-2.5

Reduce dose if CrCl less than 60mL/min

36
Q

bivalirudin dosing

A

HIT or UFH alternative during PCI:

0.7 mg/kg bolus + 1.75 mg/kg/h infusion

37
Q

bivalirudin SE

A

bleeding

38
Q

argatroban dosing

A

HIT:
2 mcg/kg/min
0.5 mcg/kg/min if hepatic insufficiency

39
Q

argatroban SE

A

bleeding

40
Q

argatroban monitoring

A

Elevates INR falsely; overlap with warfarin until INR ≥4

41
Q

dabigatran dosing

A 
DVT/PE treatment after 5-10 days parenteral anticoag:
150mg PO BID for CrCl ≥30 mL/min
NV atrial fibrillation:
150mg PO BID if CrCl >30 mL/min
75mg PO BID if 15-30 mL/min
42
Q

dabigatran SE

A

Dyspepsia
Bleeding
Keep in manufacturer bottle

43
Q

dabigatran monitoring

A

do not use in > 75

44
Q

alteplase dosing

A

10mg IV bolus + 90mg infusion over 2 hours

Most commonly for PE

45
Q

alteplase SE

A

bleeding

46
Q

reteplase dosing

A

10 units IV over 2 minutes + second dose in 30 mins

For ACS only

47
Q

reteplase SE

A

bleeding

48
Q

tenecteplase dosing

A

30mg + 5mg/10kg over 60kg up to 50mg as IV bolus

For ACS only

49
Q

tenecteplase SE

A

bleeding

50
Q

urokinase dosing

A

VTE treatment:
4400 units/kg bolus over 10 minutes
+ 4400 units/kg/hour for 12 hours

51
Q

urokinase SE

A

bleeding

52
Q

warfarin SE

A

bleeding

pregnancy X

53
Q

warfarin monitoring

A

CYP2C9, 3A4, 2C19, 1A2 interactions

Goal INR 2.0 – 3.0
*mechanical mitral/caged ball/high risk artificial valve
goal INR 2.5 - 3.5

module 2b (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions